LivaNova (NASDAQ:LIVN) Rating Increased to Buy at StockNews.com

LivaNova (NASDAQ:LIVN) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “buy” rating in a report released on Thursday.

A number of other equities research analysts have also weighed in on LIVN. Mizuho reissued a “buy” rating and issued a $75.00 target price on shares of LivaNova in a research note on Wednesday, March 27th. Robert W. Baird upped their price target on LivaNova from $56.00 to $62.00 and gave the company a “neutral” rating in a research report on Thursday, February 22nd. Barclays upped their price target on LivaNova from $57.00 to $61.00 and gave the company an “equal weight” rating in a research report on Monday, February 26th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $72.00 price target on shares of LivaNova in a research report on Wednesday, March 20th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $64.40.

LivaNova Price Performance

LIVN opened at $55.53 on Thursday. LivaNova has a 12-month low of $42.75 and a 12-month high of $59.86. The company has a current ratio of 2.95, a quick ratio of 2.51 and a debt-to-equity ratio of 0.44. The stock has a 50-day moving average price of $54.13 and a 200-day moving average price of $50.65. The stock has a market capitalization of $3.00 billion, a P/E ratio of 173.54 and a beta of 0.89.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, February 21st. The company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.10. LivaNova had a return on equity of 12.23% and a net margin of 1.53%. The company had revenue of $310.10 million during the quarter, compared to analyst estimates of $287.65 million. During the same quarter in the previous year, the company posted $0.81 EPS. LivaNova’s revenue for the quarter was up 12.8% on a year-over-year basis. Equities analysts predict that LivaNova will post 3.01 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of LIVN. Headlands Technologies LLC purchased a new position in shares of LivaNova during the 3rd quarter worth approximately $72,000. Picton Mahoney Asset Management purchased a new position in shares of LivaNova during the 3rd quarter worth approximately $91,000. Vanguard Personalized Indexing Management LLC purchased a new position in shares of LivaNova during the 3rd quarter worth approximately $217,000. AlphaMark Advisors LLC purchased a new position in shares of LivaNova during the 3rd quarter worth approximately $244,000. Finally, Jump Financial LLC purchased a new position in shares of LivaNova during the 3rd quarter worth approximately $273,000. Institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.